The New York Center for Travel and Tropical Medicine Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2020
NCT04501380
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Bradley A. Connor, M.D. | Bradley Connor | The New York Center for Travel and Tropical Medicine

Active Ingredients

Drugs in Phase 2 Trials (1)

rifamycin (aemcolo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Digestive System Diseases (Phase 2)

Gastrointestinal Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1